The Riverside Company, a global private equity firm, bought a stake in Simcro Limited, a New Zealand firm that manufactures innovative delivery systems for animal production.
Simcro has a well-established market with international pharmaceutical companies which distribute the tools and apparatus to their clients to dispense vaccines and drugs. It has set-up its presence in North and South America, Europe, Asia and Australia.
Simon Feiglin, Riverside Company partner, said they will leverage on their expertise to try to expand Simcro's business worldwide. Riverside currently has a portfolio of over 75 companies with an estimated value of US $250 million.
"The animal health industry is growing thanks to expanding demand globally," he said.
Simcro possesses strong research and development system as it continually designs prototypes for injectors and applicators in order to administer medicines and vaccines to livestock and poultry. It also subjects its products to rigorous tests before putting them out to the market.
Join the Conversation